Senator Baldwin Introduces Bill to Cap Prescription Drug Costs
The Capping Prescription Costs Act would cap annual out-of-pocket prescription drug costs per year at $2,000 for individuals and $4,000 for families
The Capping Prescription Costs Act would cap annual out-of-pocket prescription drug costs per year at $2,000 for individuals and $4,000 for families
WASHINGTON, D.C. – U.S. Senator Tammy Baldwin (D-WI) joined a group of her colleagues in introducing the Capping Prescription Costs Act, legislation that would lower prescription drug costs for millions of Americans by placing annual caps on out-of-pocket costs for prescription drugs at $2,000 for individuals and $4,000 for families with private insurance. This legislation builds on the success of the Baldwin-backed Inflation Reduction Act, which capped prescription drug costs for seniors, extending the savings to the commercial health care market.
Over 60 percent of American adults take at least one prescription drug, with 25 percent of adults taking four or more. Yet Americans often pay more for the same prescription drugs than people in other countries, and due to the cost burden, American patients often cannot afford their medications as prescribed. This results in patients skipping doses, cutting doses in half, or taking over-the-counter medications instead of their prescriptions. One study found that 31 percent of patients did not take their medications as prescribed due to cost. The new $2,000 cap on cost-sharing for individuals and $4,000 for families will apply to all of the 173 million Americans who have private health insurance.
Senator Baldwin has long championed bringing down prescription drug costs. In August 2022, Senator Baldwin helped pass the Inflation Reduction Act (IRA) to lower health care and prescription drug costs for older adults, people with disabilities, and families across the nation. Starting in January 2023, the IRA capped the cost of insulin for Medicare Part D beneficiaries at $35 a month for certain covered insulin products.
Senator Baldwin also launched an investigation into the extremely high prices four large pharmaceutical companies charge for inhalers that 25 million Americans with asthma and 16 million Americans with chronic obstructive pulmonary disease (COPD) rely on to breathe. In just two months after the investigation was launched, three of the four pharmaceutical companies capped their out-of-pocket costs for their inhaler products at $35 per month in the United States.
This legislation is led by Senator Raphael Warnock (D-GA) and is co-sponsored by Senators Cory Booker (D-NJ), Richard Blumenthal (D-CT), John Fetterman (D-PA), Kirsten Gillibrand (D-NY), Martin Heinrich (D-NM), Andy Kim (D-NJ), Amy Klobuchar (D-MN), Patty Murray (D-WA), and Peter Welch (D-VT).
NOTE: This press release was submitted to Urban Milwaukee and was not written by an Urban Milwaukee writer. While it is believed to be reliable, Urban Milwaukee does not guarantee its accuracy or completeness.
Mentioned in This Press Release
Recent Press Releases by U.S. Sen. Tammy Baldwin
Senator Baldwin Introduces Bill to Cap Prescription Drug Costs
Feb 14th, 2025 by U.S. Sen. Tammy BaldwinThe Capping Prescription Costs Act would cap annual out-of-pocket prescription drug costs per year at $2,000 for individuals and $4,000 for families
Senator Baldwin Exposes Trump Administration Halt on Lifesaving Research, Despite Court Orders
Feb 14th, 2025 by U.S. Sen. Tammy BaldwinNEW: Baldwin reveals that NIH has awarded zero grants in 10 days and is failing to fund research projects, including to find a cure for Alzheimer’s disease